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Abstract: The p.R577X polymorphism (rs1815739) in the ACTN3 gene causes individuals with the
ACTN3 XX genotype to be deficient in functional α-actinin-3. Previous investigations have found
that XX athletes are more prone to suffer non-contact muscle injuries. This investigation aimed to
determine the influence of the ACTN3 R577X polymorphism in the injury epidemiology of elite
endurance athletes. Using a cross-sectional experiment, the epidemiology of running-related injuries
was recorded for one season in a group of 89 Spanish elite endurance runners. ACTN3 R577X
genotype was obtained for each athlete using genomic DNA samples. From the study sample, 42.7%
of athletes had the RR genotype, 39.3% had the RX genotype, and 18.0% had the XX genotype. A
total of 96 injuries were recorded in 57 athletes. Injury incidence was higher in RR runners (3.2
injuries/1000 h of running) than in RX (2.0 injuries/1000 h) and XX (2.2 injuries/1000 h; p = 0.030)
runners. RR runners had a higher proportion of injuries located in the Achilles tendon, RX runners
had a higher proportion of injuries located in the knee, and XX runners had a higher proportion
of injuries located in the groin (p = 0.025). The ACTN3 genotype did not affect the mode of onset,
the severity, or the type of injury. The ACTN3 genotype slightly affected the injury epidemiology of
elite endurance athletes with a higher injury rate in RR athletes and differences in injury location.
However, elite ACTN3 XX endurance runners were not more prone to muscle-type injuries.
Keywords: athletic performance; exercise-related injury; single nucleotide polymorphism; track and
field athlete; α-actinin-3 deficiency
1. Introduction
The status of elite athlete requires many hours of strenuous training per week that
can impose severe physiological and mechanical stress on the human body, ultimately
leading to sports injuries. For this reason, injury is an inherent feature of elite sport [1], and
injury prevention has become a key aspect of every conditioning program. Because injuries
may inhibit regular training, negatively impact sports performance, and even shorten an
athlete’s career, the study of all the risk factors that predispose to injury is essential to
design effective injury prevention programs.
Endurance running is a sports discipline with an elevated injury incidence due to the
high mechanical load produced by weight-bearing and the high running mileage necessary
to prepare for endurance competitions [2]. For this reason, a high proportion of injuries in
elite endurance runners are muscle or tendon overuse injuries, and the main sites of injury
location are lower leg and knee [3,4]. Age, training volume, history of previous injuries,
and running kinematics have been considered as the main determinants for the likelihood
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of suffering endurance running injuries [4,5]. However, genetics might also play a role
in the predisposition to injury in some athletes [6], particularly the variations in genes
associated with muscle and tendon proteins [7].
α-Actinin-3 is a key component of the skeletal muscle Z-disk in fast-twitch muscle
fibers. Hence, it is believed that α-actinin-3 is important for the production of forceful
muscle contractions or to resist muscle damage induced by eccentric contractions [8]. A
single nucleotide polymorphism (p.R577X; rs1815739) in the ACTN3 gene (the gene that
codifies α-actinin-3) results in the replacement of an arginine (R) with a premature stop
codon (X) [9]. Homozygosity for this stop codon (XX genotype) produces an α-actinin-3
deficiency, as opposed to individuals with RX or RR genotypes that express functional α-
actinin-3 [10]. Although an α-actinin-3 deficiency is compensated for by a higher expression
of α-actinin-2, significant evidence has shown that XX individuals are underrepresented in
elite power-oriented athletes, which might be indicative of a negative effect of this genotype
on the function of fast-twitch muscle fibers [11].
Recent investigations have found that XX athletes might also be more prone to suffer
sports-related muscle injuries when compared to RR counterparts [12–14], although this
is not always the case [15]. There is greater consensus on the higher predisposition of XX
individuals to ankle sprains [16–18] and high levels of muscle damage during endurance
competitions [19,20]. All this information suggests an a priori predisposition of XX athletes
to sports-related injuries, but a lack of replication is present for most current findings that
associate genetics with a predisposition to sports injury, as recently suggested [21]. For this
reason, we aimed to determine the influence of the ACTN3 R577X polymorphism on the
injury epidemiology of elite endurance athletes, following the methodology of a previous
investigation carried out on amateur endurance runners [12]. We obtained information to
characterize the influence of this polymorphism on injury epidemiology, such as incidence,
conditions, severity, mode of onset, body location, and cause that led to each injury in elite
runners with different ACTN3 genotypes. We hypothesized that elite endurance runners
with the XX genotype would have a higher incidence of muscle and ligament injuries when
compared to RX and RR athletes.
2. Materials and Methods
2.1. Participants
Initially, 97 elite Spanish Caucasian endurance athletes volunteered to participate in
the study. Participants were cataloged as elite endurance athletes because they competed
in national and international events of middle- and long-distance modalities (from 800 m
to the marathon). Among them, there were 5 medallists and 20 finalists in International
Championships, and 12 champions and 23 medallists in National endurance running
competitions. For this sample, two participants were excluded by age (>45 years), and six
were excluded because their ACTN3 genotype was not clearly identified in the genotyping
analysis. Age, anthropometric characteristics, running experience, and training status of the
final study sample of 89 elite endurance runners are depicted in Table 1. The study protocol
conformed to the Declaration of Helsinki for Human Research of 1974 (last modified in
2013) and was approved by the Camilo José Cela University Ethics Committee. Written
informed consent was obtained from all participants.
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Table 1. Age, anthropometric characteristics, running experience, and training status of Spanish elite
endurance athletes with different ACTN3 R577X genotypes.
Variable (units) RR RX XX p-Value
Number (frequency, %) 38 (42.7) 35 (39.3) 16 (18.0) -
Men (frequency, %) 16 (42.1) 24 (68.6) 8 (50.0)
0.072Women (frequency, %) 22 (57.9) 11 (31.4) 8 (50.0)
Age (years) 22.8 ± 4.2 24.5 ± 10.5 26.6 ± 7.0 0.422
≤20 years (frequency, %) 13 (34.2) 11 (31.4) 5 (31.3)
0.078>20 years ≤ 30 years (frequency, %) 23 (60.5) 21 (60.0) 6 (37.5)
<30 years (frequency, %) 2 (5.3) 3 (8.6) 5 (31.3)
Height (cm) 170.2 ± 7.2 172.3 ± 8.4 172.2 ± 6.7 0.353
Body mass (kg) 56.4 ± 8.3 58.1 ± 8.6 57.1 ± 6.3 0.639
Experience (years) 11.5 ± 4.9 12.6 ± 4.9 14.7 ± 6.8 0.098
Endurance running (hours/year) 639 ± 248 650 ± 174 623 ± 237 0.770
Resistance training (hours/year) 152 ± 72 148 ± 67 129 ± 64 0.461
Competitions (number/year) 16.1 ± 6.6 17.5 ± 8.5 16.7 ± 7.1 0.780
Data are mean ± standard deviation (SD) for each genotype.
2.2. Experimental Design
This investigation was a cross-sectional experiment to determine the effect of the
ACTN3 R577X genotype (RR vs. RX vs. XX) on the injury epidemiology of endurance
running-related injuries suffered by elite endurance athletes. For this investigation, par-
ticipants completed an ad hoc questionnaire between September and November of 2019,
seeking to record non-contact injuries sustained during the previous season retrospectively.
Only injuries resulting from their training routines or competitions in endurance running
activities were recorded. The questionnaire was based on the consensus statement on
injury definitions and data collection in epidemiological studies in athletics [22].
2.3. Experimental Protocol
In the questionnaire, a recordable injury was defined as a physical complaint or
visible damage to any part of the lower limbs sustained by the athlete and assessed by a
qualified medical/healthcare practitioner. The injury was recorded irrespective of whether
it produced a time loss from training and/or competition or whether it was only a medical
attention injury that did not impede normal training. All traumatic injuries, such as the
ones caused by a fall or due to contact with an obstacle or another athlete, were discarded
as they are not potentially affected by the ACTN3 genotype. Training exposure was defined
as any physical activity conducted under the control or guidance of the coach, with the role
of maintaining or improving the athlete’s physical condition. Competition exposure was
defined as physical activities conducted in official endurance running competitions. The
questionnaire gathered information about the number of injuries sustained in the previous
season. Afterward, the information on type, severity, body location, exposure, recurrence,
mode of onset, and the possible cause that led to the injury was obtained independently for
each recordable injury, following the methodology described by Moreno-Pérez et al. [12].
The questionnaire also gathered information about training routines (endurance running
hours per week, resistance training hours per week, number of training weeks per year,
number of competitions). Hence, injury incidence was calculated for each athlete as number
of injuries per year and as number of injuries per 1000 h of endurance running.
2.4. Genetic Testing
Once participants had completed the questionnaire, they were asked to provide two
buccal swab samples using self-guided instructions. The samples were stored in envelopes,
and genomic DNA was isolated afterward using an organic-based DNA extraction method
adapted to Amicon® (Sigma–Aldrich, Madrid, Spain). DNA was extracted within 30 days
after sample collection, and the sample was eluted in 50 µL. Positive controls for all geno-
types were obtained from the Mexican branch of the CANDELA Consortium. Genotyping
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of the ACTN3 rs1815739 polymorphism (c.1858C>T; p.R577X) was conducted using a Taq-
Man SNP Genotyping Assay (Assay ID: C___590093_1_; Applied Biosystems, Foster City,
CA, USA), and the reaction was performed in an Applied Biosystems 7500 Fast Real-Time
PCR System (Applied Biosystems).
2.5. Statistical Analysis
Data on injury epidemiology were transferred from the questionnaire to an ad hoc
database. The normality of each variable was initially tested with the Kolmogorov–Smirnov
test and parametric/non-parametric statistics were performed for normally/non-normally
distributed variables, respectively. For the continuous variables, genotype comparisons (RR
vs. RX vs. XX) were performed using a one-way analysis of variance (ANOVA; followed by
Tukey’s post-hoc comparisons) or the Kruskal–Wallis test. For the variables presented as
frequency, the differences in distribution among genotypes were identified with crosstabs
and χ2 tests, including adjusted standardized residuals. Compliance of Hardy–Weinberg
Equilibrium (HWE) in the genotype distribution of the sample was tested using χ2 tests.
Spearman’s rho was used to calculate the association between training volume and the
number of injuries per year. All statistical analyses were performed with statistical software
(SPSS Statistics 22, IBM Armonk, NY, USA). Descriptive data are presented as means and
standard deviations. Statistical significance was set at p < 0.05.
3. Results
Genotyping for ACTN3 R577X was successful in 89 out of 95 participants (93.7%
of successful genotyping). From the final study sample, 38 (42.7%) athletes had the RR
genotype, 35 (39.3%) athletes had the RX genotype, and 16 (18.0%) had the XX genotype
(Table 1). The genotype distribution met the HWE. There was no difference in the propor-
tion of men/women elite endurance athletes among genotypes nor in age, anthropometric
characteristics, or training variables.
Of the study participants, 32 athletes reported no injury during the preceding season,
while the remaining 57 athletes reported a total of 96 injuries. There were no differences in
the distribution of athletes with/without injury across the different ACTN3 genotypes in
the whole sample or when analyzing the subsamples of male and female elite endurance
athletes (Table 2). The injuries were recorded by a physician (62.1%), by a physiotherapist
(32.6%), or by other healthcare providers (5.3%). From the total, 37.9% of injures were
diagnosed by magnetic resonance imaging, 28.7% by echography, 4.6% by X-ray, and 28.7%
by other clinical testing.
Table 2. Distribution of athletes with/without an injury reported in the preceding season according to their ACTN3 R577X
genotype.
Variable (units) RR RX XX p-Value
Total
Athletes with injury (frequency, %) 23 (60.5) 24 (68.6) 10 (62.5)
0.766Athletes without injury (frequency, %) 15 (39.5) 11 (31.4) 6 (37.5)
Males
Athletes with injury (frequency, %) 8 (50.0) 19 (79.2) 5 (62.5)
0.153Athletes without injury (frequency, %) 8 (50.0) 5 (20.8) 3 (37.5)
Females
Athletes with injury (frequency, %) 15 (62.8) 5 (45.5) 5 (62.5)
0.449Athletes without injury (frequency, %) 7 (31.8) 6 (54.5) 3 (37.5)
Data are numbers and frequencies (in percentage) of athletes with/without injury reported in the preceding season from the total number
of athletes or the number of athletes in each sex.
There were no differences in the mean value of injuries per year, nor in the distribution
of the number of injuries per year among genotypes (Table 3). However, the median
value for injury incidence was higher in RR (3.2, range from 0.8 to 7.4 injuries/1000 h of
running) runners than in RX (2.0, range from 0.9 to 7.4 injuries/1000 h of running) and
XX (2.2, from 0.9 to 6.3 injuries/1000 h of running; p = 0.030) runners. Table 3 depicts
epidemiological information about injury conditions in the sample of elite endurance
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runners. The ACTN3 genotype did not affect the proportion of time loss/medical attention
injuries, the severity of the injury, the distribution of training and competition injuries, the
proportion of recurrent injuries, the mode of onset, or the possible cause that led to the
injury. However, RR runners had a higher proportion of injuries located in the Achilles
tendon, RX runners had a higher proportion of injuries located in the knee, and XX runners
had a higher proportion of injuries located in the groin (Table 4, p = 0.025). Finally, the
ACTN3 genotype did not affect the type of injury with a similar distribution of muscle,
bone, tendon, and ligament injuries.
Table 3. Injury incidence, distribution of athletes according to the number of injuries, and distribution
of injuries according to severity, exposure, recurrence, mode of onset, and possible cause in elite
endurance runners with different ACTN3 R577X genotypes.
Variable All RR RX XX p-Value
Incidence
/per year 1.0 1.0 1.0 1.0 0.321
/1000 h or running 2.8 3.2 2.0 2.2 0.030
Number
No injury (%) 36.0 39.5 31.4 37.5
0.177
1 injury (%) 31.5 21.1 40.0 37.5
2 injuries (%) 21.3 18.4 22.9 25.0
≥3 injuries (%) 11.2 21.1 5.7 0.0
Time loss
Medical attention (%) 9.2 7.1 10.3 11.8
0.819Time loss (%) 90.8 92.9 89.7 88.2
Severity
Minor (%) 13.4 12.9 12.7 16.0
0.993Moderate (%) 51.4 51.6 52.7 48.0
Serious (%) 35.2 35.5 34.5 36.0
Exposure Training (%) 94.9 95.3 94.9 94.1 0.981Competition (%) 5.1 4.7 5.1 5.9
Recurrence
New onset (%) 61.2 59.5 66.7 52.9
0.598Recurrent (%) 38.8 40.5 33.3 47.1
Mode of onset
Sudden (%) 46.9 45.2 43.6 58.8
0.552Gradual (%) 53.1 54.8 56.4 41.2
Possible cause
Excessive load (%) 62.2 61.9 61.5 64.7
0.526
Surface (%) 11.2 11.9 15.4 0.0
Shoe (%) 8.2 4.8 7.7 17.6
Biomechanics (%) 4.1 7.1 2.6 0.0
Unknown (%) 14.3 14.3 12.8 17.6
Data are frequencies (in percentage) from the total of injuries recorded in each genotype.
Table 4. Distribution of injuries according to body location and type of injury in elite endurance runners with different
ACTN3 R577X genotypes.
Variable All RR RX XX p-Value
Body location
Groin (%) 13.5 4.8 * 13.2 37.5 *
0.025
Hip (%) 1.0 2.4 0.0 0.0
Thigh (%) 15.6 14.3 13.2 25.0
Knee (%) 10.4 4.8 21.1 * 0.0
Lower leg (%) 15.6 21.4 13.2 6.3
Achilles tendon (%) 11.5 19.0 * 7.9 0.0
Ankle (%) 9.4 4.8 13.2 12.5
Foot (%) 16.7 19.0 13.2 18.8
Other (%) 6.3 9.5 5.3 0.0
Type of injury
Strain/muscle rupture (%) 19.6 22.7 15.0 22.2
0.295
Stress fracture/other bone injury (%) 13.7 11.4 10.0 27.8
Tendinosis/tendinopathy (%) 33.3 31.8 40.0 22.2
Sprain/ligament injury (%) 7.8 2.3 12.5 11.1
Other (%) 25.5 31.8 22.5 16.7
Data are frequencies (in percentage) from the total of injuries recorded in each genotype. (*) Different from expected value at p < 0.05.
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4. Discussion
In an attempt to increase the scarce knowledge available about the influence of genetics
on elite athlete’s susceptibility to injury, we designed a cross-sectional investigation to
assess the influence of the ACTN3 R577X polymorphism on injury epidemiology in elite
endurance athletes. This investigation replicates the methods used in a previous study [12],
with the only difference being the characteristics of the study sample (elite vs. amateur
endurance runners). The main conclusions of this investigation indicate that the ACTN3
genotype had a slight but interesting influence on injury epidemiology of elite endurance
athletes. Specifically, there was a higher injury rate in RR athletes than in RX and XX
genotypes, and there were differences in injury location. However, our main hypothesis
related to a higher incidence of muscle injuries in XX athletes has not been confirmed with
the current data.
The overall injury incidence was 2.8 injuries per 1000 h of endurance running, and
64% of the sample reported at least one injury during the preceding season, which is in
agreement with previous data on elite samples [23,24]. Additionally, the number of injuries
per year was associated with endurance running volume/year (Spearman’s rho = 0.259;
p = 0.014), suggesting that a high running mileage was an important injury risk factor in
this sample of elite endurance runners as previously found in other types of endurance
runners [25,26]. However, the number of injuries per 1000 h of endurance running was
45–60% higher in RR athletes than in RX and XX counterparts. This higher incidence was
produced because 21% of the RR athletes sustained three injuries or more (Table 3), while
no XX runner sustained ≥ 3 injuries. This is not a unique finding in the literature as a
higher injury incidence of RR vs. RX-XX has also been found in amateur runners [12] and
in women college athletes [15]. The higher injury incidence among the individuals with a
full expression of α-actinin-3 (RR genotype) may be explained by higher levels of muscle
strength and a lower range of motion [27,28], which could be translated into more physical
stress and lesser joint mobility that ultimately produced an injury.
When taking a close look at injury location, RR had an unusual frequency of injuries
located in the Achilles tendon (Table 4), while no XX athlete has reported Achilles tendon
injuries in this sample of elite athletes, nor in a sample of amateur runners [12]. In amateur
marathoners, XX runners have higher ankle dorsiflexion than RR runners [29]. Interestingly,
limited ankle dorsiflexion may increase the risk for mid-portion Achilles tendinopathy in
runners [30] and military personnel carrying out a physical training program [31]. Together,
all this information suggests that elite RR endurance athletes might be more prone to suffer
an overall injury incidence rate, particularly because a high proportion of runners had
three or more injuries per year and had an abnormal proportion of Achilles tendon injuries,
at least when compared to RX and XX counterparts.
On the contrary, a higher injury incidence of non-contact muscle injuries has been
previously reported in amateur athletes [12] and professional football players [13,14].
These investigations indicate that, when isolating muscle-type injuries, XX athletes are
1.8–2.6 times more likely to suffer a non-contact sports injury than RR genotypes. The
current investigation does not confirm this outcome because the proportion of muscle
strains and muscle ruptures in XX elite athletes was not different from the other two
genotypes. The explanation for the lack of higher susceptibility to muscle injuries in
our sample of XX elite athletes might be related to their excellent training conditions. In
addition to the time devoted to endurance running, this sample of athletes had an average
of 148 ± 67 h/year resistance exercise training. The incorporation of resistance training
within the physical conditioning program of elite endurance athletes has become more
usual in the last few years as this type of training might be effective in enhancing running
efficiency but also in improving muscle power and overall performance [32]. Thus, it is
possible that the inclusion of a resistance training program at the elite level may have
helped to offset the lower strength values found in XX endurance athletes with a low
background of resistance training [29]. The current data dispute the notion that catalogues
XX athletes as more prone to muscle injuries because research is inconsistent, and the risk
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of muscle injury according to different ACTN3 genotypes may be sports-specific. Moreover,
it suggests that the potential predisposition of XX sportspeople to muscle-type injury might
be overcome by strength training. This is a speculation that merits further investigation.
An interesting outcome of this investigation with elite endurance athletes is the high
incidence of groin injuries in XX athletes with respect to the RR and RX genotypes. In
the current investigation, one out of three injuries reported by XX runners was located
in the groin area, despite this being a body location with a relatively low frequency of
injury in endurance runners [24]. The second most common location in XX was the thigh,
with a frequency that was double that of RR and RX counterparts. In amateur endurance
runners, the knee and the lower leg are the most common body locations for running-
related injuries [26,33], particularly in XX runners [12]. During running at low speeds,
propulsion is achieved mainly by the structures of the lower leg and soleus, and the
gastrocnemius muscles have a particularly important role. At running speeds close to or
up to 20 km/h, the capacity of lower leg muscles becomes less relevant, and locomotion
is based on the action of the iliopsoas, gluteus maximus, and rectus femoris [34]. In this
sample of elite endurance runners, running speeds above 20 km/h are commonly achieved
during training and competition, which indicates a high contribution of proximal lower
limbs muscles. In this respect, amateur XX runners might be more prone to lower leg
injuries, while elite XX runners might be more prone to groin and thigh injuries due to the
differences in running speed attained by each group.
The experimental design employed in this investigation presents some limitations
that should be addressed to enhance the application of the results. First, the sample size is
relatively low, and the extraction of any definitive conclusions about the final association
of ACTN3 genotype and injury epidemiology in elite runners should be made with caution
because studies with small sample sizes are more prone to present hidden biases, such
as population stratification and cryptic relatedness. Therefore, future investigations in
elite runners should be carried out to replicate the results of this study. Additionally,
the study sample was composed of elite endurance runners, and the translation of the
research outcomes to less trained athletes should be made with caution. This is important
as the effect of ACTN3XX genotype to increase the incidence of non-contact muscle injury
may be higher in amateur than in elite counterparts. Second, the external load of the
runners across the year studied, measured as endurance and resistance training volume,
was not standardized. Although there were no differences in the number of hours/years
devoted to endurance and resistance training among genotype groups (Table 1), future
investigations should use experimental designs in which the training and competition load
imposed on elite runners is standardized among genotypes. Last, the current investigation
only reported recorded injuries that required medical attention and time loss from regular
training, while there was no information recorded about complaints that athletes suffered
across the year which were not assessed by a qualified medical/healthcare practitioner.
Therefore, this characteristic of the experimental design may have biased the results because
all severe injuries were recorded, while some of the less severe injuries/complaints may
have been unreported. The effect of ACTN3 genotype on all athletic health problems,
irrespective of its consequences on the athlete’s sports participation, or whether the athlete
sought medical attention should be investigated, following the recommendations of the
International Olympic Committee consensus statement for recording and reporting of
epidemiological data on injury in sport [35].
5. Conclusions
In summary, the ACTN3 genotype slightly affected the injury epidemiology of elite
endurance athletes with a higher injury rate in RR athletes and subtle differences in injury
location. Despite the above-discussed differences, the ACTN3 genotype did not affect
the proportion of time-loss injuries, the severity of the injury, the distribution of training
and competition injuries, the proportion of recurrent injuries, the mode of onset, or the
possible cause that led to the injury. Regardless of the data obtained in the present study,
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the evidence linking genetics and injury epidemiology is still emerging, and in the authors’
opinion, it is premature to use genetic testing among elite middle/long-distance runners to
effectively predict the risk of injury.
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